BMS-986253, HuMax-IL8, HuMax-Inflam/MDX018 Product NameBMS-986253, HuMax-IL8, HuMax-Inflam/MDX018 CAS MF MW0 EINECS MOL FileMol File BMS-986253, HuMax-IL8, HuMax-Inflam/MDX018 Supplier
Patients were randomly assigned 1:1 to receive 3600 mg of BMS-986253 once every 2 weeks plus 1 mg/kg of nivolumab once every 3 weeks and 3 mg/kg of ipilimumab once every 3 weeks for the first 12 weeks, followed by 3600 mg of BMS-986253 once every 2...
BMS-986253, a fully human IgG1κ anti–IL-8 mAb, binds IL-8 and prevents signaling through CXCR1/CXCR2. We present updated results from part 1 of the phase 1/2 trial of BMS-986253 + NIVO± IPI in pts with advanced cancer (NCT03400332)....
英文名称:BMS-986253, HuMax-IL8, HuMax-Inflam/MDX018 英文同义词:BMS-986253, HuMax-IL8, HuMax-Inflam/MDX018 CAS号: 分子式: 分子量:0 EINECS号: 信息错误报告 您的Email: 按国家浏览BMS-986253, HuMax-IL8, HuMax-Inflam/MDX018国外供应商中国供应商 ...